secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0001493152-24-009737
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Biosciences reports record FY2023 revenue $40.2M (+26% YoY), swings to profit of $1.1M.
--------------------------------------------------------------------------------

- Q4 revenue $10.3M (+23% YoY); Q4 income from cont. ops $0.8M vs loss of $1.4M in prior year.
- FY2023 adjusted EBITDA $4.5M (net of one-time charges) vs -$1.2M in 2022, a 463% reported improvement.
- Cash collections for FY2023 $40.4M (+29% YoY); cash balance at Dec 31, 2023 was $3.5M.
- Dr. Nicole Massoll appointed Chief Medical Officer effective March 2024.
- 10-K expected week of March 19, 2024; preliminary results subject to final audit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315224009737/0001493152-24-009737-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315224009737/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-009737

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer